2025年,是爱尔康进入中国市场的第30个年头。对于这家拥有近80年历史的全球眼科巨头而言,站在新的节点上,面前铺开的,是一个充满挑战与惊喜的开局。挑战在于,中国市场从未像今天这样复杂。无论是政策环境、患者需求层次还是支付体系,变化都在加速演进,尤其是人工晶体国采的落地,打破了过往惯性,让整个眼科手术市场迎来一次深度重构。令人惊喜的是,在这场风暴中,爱尔康不仅稳住了脚跟,而且表现出色,成为为数不多...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.